Alyeska Investment Group
HRTX icon

Alyeska Investment Group’s Heron Therapeutics HRTX Stock Holding History

Alyeska Investment Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-775,299
Closed -$21.4M – 486
2018
Q1 		$21.4M Sell
775,299
-544,646
-41% -$12.4M 0.18% 147
2017
Q4 		$23.9M Buy
1,319,945
+565,288
+75% +$9.22M 0.19% 138
2017
Q3 		$12.2M Buy
754,657
+65,260
+9% +$1.02M 0.09% 225
2017
Q2 		$9.55M Sell
689,397
-106,934
-13% -$1.55M 0.08% 243
2017
Q1 		$11.9M Buy
796,331
+272,734
+52% +$3.77M 0.1% 243
2016
Q4 		$6.86M Buy
523,597
+327,255
+167% +$5.13M 0.06% 302
2016
Q3 		$3.38M Buy
+196,342
New +$3.64M 0.03% 352
2015
Q2 		– Sell
-156,268
Closed -$2.27M – 525
2015
Q1 		$2.27M Sell
156,268
-15,286
-9% -$172K 0.03% 355
2014
Q4 		$1.73M Buy
171,554
+45,885
+37% +$374K 0.03% 353
2014
Q3 		$1.05M Buy
+125,669
New +$1.17M 0.02% 322
2014
Q1 		– Sell
-50,000
Closed -$445K – 359
2013
Q4 		$445K Buy
+50,000
New +$445K 0.02% 285

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Alyeska Investment Group's HRTX Position: Q2 2018 in Review

Alyeska Investment Group sold out of Heron Therapeutics (HRTX) in Q2 2018, closing a stake of 775,299 shares — an estimated $21.4M sold.

Alyeska Investment Group first reported a position in HRTX in Q4 2013 and held it in 11 quarters. The position peaked at $23.9M in Q4 2017. 196 funds tracked by Wall St. Rank hold HRTX as of Q2 2018.

  • Alyeska Investment Group reported no remaining Heron Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 775,299 Heron Therapeutics shares in Q2 2018, an estimated $21.4M.
  • Alyeska Investment Group first reported a position in Heron Therapeutics in Q4 2013 and held it in 11 quarters.
  • Alyeska Investment Group's Heron Therapeutics position peaked at $23.9M in Q4 2017.
  • 196 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2018.

Based on Alyeska Investment Group's 13F filing for Q2 2018, filed 14 Aug 2018.